Keywords: Shire, Advanced BioHealing, Dermgraft, Regenerative medicines, Diabetic foot ulcers, Venous leg ulcers
Shire to buy regenerative medicines firm Advanced BioHealing for $750 million
Article | 18 May 2011
Ireland-headquartered biopharmaceutical firm Shire (LSE: SHP) - best known for its attention-deficit hyperactivity disorder franchise - has signed an agreement ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
